Skip to main content
NCBI home page
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2012 Dec 7;288(4):2571–2579. doi: 10.1074/jbc.M112.418848

The Involvement of CD146 and Its Novel Ligand Galectin-1 in Apoptotic Regulation of Endothelial Cells*

Nathalie Jouve ‡,1,2, Nicolas Despoix ‡,1, Marion Espeli §, Laurent Gauthier , Sophie Cypowyj ‡, Karim Fallague ‡, Claudine Schiff §,‖,**, Françoise Dignat-George ‡,‡‡, Frédéric Vély §,‖,**,‡‡,3, Aurélie S Leroyer ‡,3,4
PMCID: PMC3554924  PMID: 23223580

Background: CD146 is a glycosylated adhesion molecule involved in the control of vessel integrity.

Results: Galectin-1 directly binds to CD146 and this interaction is involved in the control of endothelial cell apoptosis.

Conclusion: Galectin-1 is identified as a novel ligand for CD146.

Significance: CD146 acts as a decoy-receptor to down-regulate Galectin-1-mediated apoptosis.

Keywords: Apoptosis, Endothelial Cell, Galectin, Glycoprotein, Ligand-binding Protein

Abstract

CD146 is a highly glycosylated junctional adhesion molecule, expressed on human vascular endothelial cells and involved in the control of vessel integrity. Galectin-1 is a lectin produced by vascular cells that can binds N- and O-linked oligosaccharides of cell membrane glycoproteins. Because both CD146 and Galectin-1 are involved in modulation of cell apoptosis, we hypothesized that Galectin-1 could interact with CD146, leading to functional consequences in endothelial cell apoptosis. We first characterized CD146 glycosylations and showed that it is mainly composed of N-glycans able to establish interactions with Galectin-1. We demonstrated a sugar-dependent binding of recombinant CD146 to Galectin-1 using both ELISA and Biacore assays. This interaction is direct, with a KD of 3.10−7 m, and specific as CD146 binds to Galectin-1 and not to Galectin-2. Moreover, co-immunoprecipitation experiments showed that Galectin-1 interacts with endogenous CD146 that is highly expressed by HUVEC. We observed a Galectin-1-induced HUVEC apoptosis in a dose-dependent manner as demonstrated by Annexin-V/7AAD staining. Interestingly, both down-regulation of CD146 cell surface expression using siRNA and antibody-mediated blockade of CD146 increase this apoptosis. Altogether, our results identify Galectin-1 as a novel ligand for CD146 and this interaction protects, in vitro, endothelial cells against apoptosis induced by Galectin-1.

Introduction

CD146, also known as S-Endo1, Melanoma Cell Adhesion Molecule (MCAM5 or Mel-CAM), MUC18, A32 antigen, is an integral membrane glycoprotein of 113 kDa that belongs to the immunoglobulin superfamily with a characteristic V-V-C2-C2-C2 domain structure (1). Using the anti-human CD146 monoclonal antibody (S-Endo1) developed in our laboratory, we have previously demonstrated that CD146 is expressed on human vascular endothelial cells, whatever vessel caliber or anatomical region (2). CD146 is also overexpressed on some tumoral cells, activated T-cell subpopulation and pericytes (3–9). It has been previously shown that in cultured endothelial cells, CD146 is concentrated at the intercellular junctions and controls inter-endothelial cell cohesion, paracellular permeability, monocyte transmigration, and angiogenesis (10–15). Moreover, antibody-mediated cross-linking of CD146 in HUVEC (Human Umbilical Vein Endothelial Cells) induces tyrosine phosphorylation of the non-receptor tyrosine kinase p59fyn, of FAK (Focal Adhesion Kinase) and of paxillin, indicating a role of CD146 in the reorganization of the cytoskeleton (16). Altogether, these data identified CD146 as an adhesion molecule of the endothelial junction. However, very few are known about its ligands. It has been reported that CD146 functions as a homophilic adhesion molecule, but this interaction is still debated as a direct biochemical evidence for homophilic interaction with the purified receptor is lacking (5, 17, 18). Laminin 411, also named α4β1γ1 integrin, that is expressed along the vascular endothelium, was recently discovered as a specific ligand for CD146 (19). In this study, the authors demonstrated that blocking the interaction of mouse CD146 with laminin 411 inhibits T cell adhesion (19).

CD146 is a highly glycosylated protein since glycosylations account for about 35% (1) of its apparent molecular weight, suggesting that this protein could interact with sugar-binding proteins such as lectins. Interestingly, Galectin-1 is a 14 kDa lectin widely expressed in mammalian organism that is produced by vascular, interstitial, epithelial, and immune cells (20). This lectin is known to specifically bind galactoside derivatives of glycoproteins on cell membranes (21). Indeed, various membrane glycoconjugates have been identified as binding partners of Galectin-1 such as β1 integrins, CD2, CD3, CD4, CD43, CD45, and GM1 ganglioside. In addition, Galectin-1 binds to a number of extracellular-matrix components in a dose-dependent and β-galactoside-dependent manner. For example, laminin and fibronectin, which are highly N-glycosylated, interact with Galectin-1 (22). Because Galectin-1 is a divalent lectin, it can also form complexes with receptor partners participating in cell-matrix recognition. Thus, Galectin-1 is a multifunctional protein involved in a variety of biological activities such as cell-matrix interactions, immune response, inflammatory response, tumorigenesis, and apoptosis of both tumor and immune cells (23, 24).

Galectin-1 and CD146 showed intriguing common biological functions. First, Galectin-1 expression knock-down in the zebrafish model results in impaired vascular network formation (25) whereas suppression of CD146 expression in the same model results in poorly developed intersomitic vessels (26), suggesting that both Galectin-1 and CD146 are involved in vascular development in this model. Second, tumor growth in Galectin-1-null mice is markedly impaired because of insufficient tumor angiogenesis (25). In a similar way, tumor growth was inhibited in mice following the administration of monoclonal antibody targeting CD146, and this effect was accompanied by a reduction of tumor blood vessel density (27). In addition, Galectin-1 is involved in melanoma progression (28, 29) as well as CD146, which level of expression was correlated with an advance tumor stage in melanoma (30). Third, Galectin-1 was described to activate VEGFR-2 signaling (31, 32), and it has been recently shown that VEGFR-2 phosphorylation is dependent of CD146 (33). Fourth, as well as CD146, Galectin-1 showed altered expression and localization in activated and tumor endothelial cells (34). Finally, it has been previously shown that endothelial cells secrete Galectin-1 upon inflammatory conditions (34). Moreover, Galectin-1 can induce apoptosis of T lymphocytes and can regulate bcl-2 expression (35, 36). Along the same line, CD146 expression is both up-regulated at the membrane and secreted after TNFα treatment (12), and its overexpression leads to activation of survival and anti-apoptotic pathways (37). These data combined with the strong glycosylation of CD146 prompted us to look for a direct interaction between endothelial CD146 and Galectin-1 protein as well as to determine its potential role in endothelial cell functions. Thus, we hypothesized that Galectin-1 could interact with CD146 and that the binding of Galectin-1 to CD146 might modulate endothelial cell apoptosis.

EXPERIMENTAL PROCEDURES

Cells

HUVEC were obtained from different donors and prepared according to a previously described protocol (38). This work has been approved by the local ethical committee N° 2006-A006-16-45 Assistance Publique Hôpitaux de Marseille. Written parental informed consents have been obtained. They were cultured on 0,2% gelatin, in EBM-2 (Endothelial Basal Medium) (Lonza, CC3156) supplemented with EGM-2 (Endothelial Growth Medium) (Lonza, CC4176). When divided, HUVEC were detached using trypsin incubation during 2 min, followed by addition of fetal calf serum, which permits trypsin neutralization.

Transfection of CD146 Complementary DNA in Fibroblastic Cell Lines

CD146 transfected fibroblasts were obtained as previously described (11). Briefly, CD146 cDNA was inserted in the EcoRI sites of the mammalian expression vector PCI-neo. The fibroblastic L929 cell line was cultured in Dulbecco modified Eagle's medium-Ham F12 supplemented with 10% FCS and was transfected using Lipofectamine (Invitrogen). The transfected cells were selected by resistance to geneticin (800 mg/ml; Invitrogen) and stable clones were obtained by dilution and 3-fold subcloning. Cells were further selected on the basis of CD146 expression determined by Western blotting and flow cytometry using S-Endo1 anti-CD146 antibody.

CD146/Galectin-1 Immunofluorescence Staining

CD146-transfected fibroblasts or endothelial progenitor cells were cultured on 0.2% gelatin-coated culture slide (BD, 354118). Cells were stimulated with 20 ng/ml of TNF-α for 20 h and washed briefly with cold PBS before incubation for 15 min in PBS containing 3% paraformaldehyde. After incubation with recombinant human Galectin-1 (5 μg/ml), cells were rinsed with PBS and permeabilized with 0.2% Triton in PBS for 5 min. Staining was performed using mouse antibody directed against human CD146, (1:200, S-Endo1), rabbit anti-Galectin-1 antiserum (1:100). Cells were washed with cold PBS and incubated with either Alexa Fluor 488-labeled goat anti-mouse (1:500) for CD146 immunostaining or Alexa Fluor 546-labeled goat anti-rabbit (1:500) for Galectin-1. Mounted slides were then analyzed using LSM 510 Zeiss confocal microscope.

Enzyme-linked Immunoadsorbent Assay (ELISA)

Human CD146-Fc was obtained as previously described for the mouse CD146-Fc (39). Briefly, CD146-Fc fusion protein contains the extracellular part of human CD146 fused to the Fc moiety of a human IgG1. The coding sequence of human extracellular CD146 was obtained by PCR using specific primers (forward 5′-GCTAGCGGAGCAGCCTGCGCCTGAG-3′, reverse 5′-GGATCCCGCCGGCTCTCCGGCTCCG-3′) and cloned in pCDM7 vector. Recombinant CD146-Fc protein was obtained after transient transfection of the COS-7 eukaryotic cell line and was purified as previously described (39). Quality and purity of CD146-Fc were assessed using Coomassie Blue and Western blotting with anti-CD146 antibodies (7A4 clone Biocytex) and HRP-coupled donkey anti-human-Ig antibodies (BD).

Human His-tagged Galectin-1 and Galectin-2 proteins were obtained and purified as previously described (40). Recombinant human ICOS Ligand Fc (Inducible T-cell COStimulator) was provided by Jacques Nunes (UMR 891, Marseille, France) and used as a negative control. 10 μg/ml of CD146-Fc proteins were coated on ELISA plate (VWR, 1315801) overnight in PBS at 4 °C. After BSA (bovine serum albumin) saturation, distinct concentrations of His-tagged Galectin-1 and Galectin-2 proteins were incubated for 1 h at room temperature. Interactions were revealed by an incubation with a monoclonal antibody directed against His tag (BD, cat 552565) followed by an incubation with donkey anti-mouse IgG-HRP (1:1000, Jackson Laboratories). Revelation was performed by addition of TMB (Tetramethylbenzidine) (Sigma, T0440-100-1). In competition experiments using sugars, galectin incubation was performed in the presence of 0.2 m of either maltose or lactose.

Surface Plasmon Resonance Assay

Surface plasmon resonance measurements were performed on a Biacore T100 apparatus (Biacore GE Healthcare) at 25 °C in HBS-EP+ buffer (10 mm Hepes, pH 7.4, 150 mm NaCl, 3.4 mm EDTA, 0.0005% surfactant P20). In all Biacore experiments, HBS-EP+ buffer (Biacore GE Healthcare) served as running buffer and sensorgrams were analyzed with Biacore T100 evaluation software. CD146- and Ligand Fc proteins were immobilized covalently to carboxyl groups in the dextran layer on a Sensor Chip CM5. The sensor chip surface was activated with EDC/NHS (N-ethyl-N′-3-dimethylaminopropyl) carbodiimidehydrochloride and N-hydroxysuccinimide (Biacore GE Healthcare). Proteins were diluted at 10 μg/ml in coupling buffer (10 mm acetate, pH 5.2) and injected until the appropriate immobilization level was reached (i.e. 600 to 800 Resonance Units RU). Deactivation of the remaining activated groups was performed using 100 mm ethanolamine pH 8 (Biacore GE Healthcare). Then, a solution of Galectin-1 (1.7 μm) was injected for 2 min through CD146-Fc and ICOS Ligand-Fc channels.

For steady state experiments, serial dilutions from 4 nm to 2 μm of soluble Galectin-1 were injected for 6 min at a constant flow rate of 40 μl/min on dextran layers containing immobilized CD146 recombinant proteins and allowed to dissociate for 1 min before regeneration by a 8 s injection of 500 mm NaCl and 10 mm NaOH buffer. The flow cell containing immobilized ICOS Ligand-Fc proteins was used as a negative control for blank subtraction.

The resulting sensorgrams were analyzed by global fitting using the appropriate model. In this model, the equilibrium dissociation constant KD is obtained by calculating the slope from a pseudo-Scatchard plotting of Req versus Req/C. The curves show the specific signal obtained after subtraction of the background (obtained using immobilized ICOS Ligand-Fc). For solution inhibition experiments, Galectin-1 proteins, at a constant concentration of 50 μg/ml, were pre-incubated with increasing concentrations of lactose or maltose (from 0 to 50 mm, Sigma Aldrich) and injected for 2 min at a flow rate of 10 μl/min onto the CD146 chips. After each cycle, sensorchips were regenerated by 8 s injection of 500 mm NaCl and 10 mm NaOH buffer at flow rate of 40 μl/min.

Analysis of CD146 Glycosylations

Deglycosylation experiments were performed using PNGase (New England Biolabs, P0704L), neuraminidase (New England Biolabs, P0720S) or α-N-acetyl galactosaminidase (New England Biolabs, P0734S). Briefly, 5 μg of CD146-Fc was heated 10 min at 100 °C with denaturing buffer and further submitted to PNGase in G7 buffer and Nonidet P-40 during 2 h at 37 °C. Either neuraminidase or galactosaminidase was directly incubated with 5 μg of protein 2 h at 37 °C.

Deglycosylated proteins were separated in 4–12% precise protein SDS-PAGE (Perbio Science, #25204). CD146 was detected by Western blot using anti-CD146 mAb (Biocytex, 7A4 clone; 1:1000) followed by HRP-conjugated anti-mouse IgG mAb (1:10000 Jackson Laboratories) and revealed by ECL Plus reagent (GE Healthcare, RPN 2132).

Assessment of Endothelial Cell Apoptosis

Endothelial cell apoptosis was determined by Annexin-V/7AAD-positive staining. HUVEC were plated in 6-well plates and incubated at 37 °C in a 5% CO2 atmosphere. All experiments were performed between passages 2 and 6. When cells reached 70% of confluence, they were stimulated with Galectin-1 during 24 h. Annexin-V/7AAD co-staining was rapidly performed after HUVEC detachment, with the Annexin-V-FITC/7AAD kit from Beckman Coulter (cat PNIM 3614). Positive cells were analyzed on a FC500 flow cytometer (Beckman Coulter). Apoptosis was also evaluated with a cell death detection ELISA kit (Roche Applied Science), according to the manufacturer's instructions.

Neutralizing anti-CD146 (S-Endo1 clone, Biocytex, cat 5050) monoclonal antibody and its corresponding isotypic control (Biocytex) were used at the final concentration of 5 μg/ml in this assay. The caspase-family inhibitor Z-VAD-FMK (Biovision, 1010–100) was used at the concentration of 2 μm.

Ribonucleic Acid (RNA)-mediated Silencing of CD146 in HUVEC

The RNA interference treatment was performed using subconfluent HUVEC cultured in antibiotic-free serum supplemented medium. Transfection of siRNA directed against CD146 (20 μm, Invitrogen, HSS181039) or control siRNA (20 μm, Invitrogen, 12935–300) was performed by nucleofection (kit HUVEC old, Lonza, VPB-1492) according to the manufacturer's instructions. Transfection efficiency was assessed by monitoring CD146 expression by flow cytometry analysis using S-Endo1 anti-CD146 mAb or isotype-matched control mAb (Biocytex, 5050) and by Western blot as previously described. Briefly, for Western blot analysis, cells were washed in PBS, submitted to trypsin action, and extracted with 500 μl of ice-cold RIPA buffer (150 mm NaCl, 50 mm Tris HCl, pH 7.4, 2.4 mm EDTA, 1% Nonidet P-40, 0.5 mm phenylmethylsulfonyl fluoride) for 30 min at 4 °C. After centrifugation (12,000 × g, 10 min, 4 °C) to eliminate cell debris and nuclei, protein extracts were submitted to 7.5% NuPage SDS-polyacrylamide gel electrophoresis (Invitrogen) and transferred onto nitrocellulose membrane (Invitrogen).

Statistical Analysis

Data are expressed as mean ± S.E.M. Student tests and Mann Whitney tests for independent samples were used. Statistical analysis was performed with Prism software for Windows (SPSS Software). Differences were considered significant at p < 0.05.

RESULTS

Galectin-1 Interacts with CD146 in Endothelial Cells

To investigate whether Galectin-1 interacts with endothelial CD146, we first performed immunoprecipitation of Galectin-1 from endothelial cells with a specific rabbit anti-Galectin-1 serum. Blotting of the resulting precipitate showed the interaction of Galectin-1 with CD146 in HUVEC (Fig. 1A). Pre-immune rabbit serum, used as negative control (IP control, Fig. 1A), was not able to precipitate CD146 and Galectin-1 from endothelial cells. We further performed several immunofluorescence analyses by confocal microscopy to detect a colocalization of CD146 and Galectin-1. Once secreted, Galectin-1 binds rapidly to the surface of many cell surface proteins and to the extracellular matrix. This feature makes difficult the identification of a specific colocalization of CD146 and Galectin-1. Nevertheless a partial colocalization of CD146 and Galectin-1 was observed when CD146-transfected fibroblastic cell line was exposed to exogenous Galectin-1 (Fig. 1B). To test whether endogenous Galectin-1 could also colocalize with endothelial CD146, endothelial cells were stimulated with TNF-α, described to induce Galectin-1 secretion. We also detected some colocalization areas using endothelial progenitor cells (Fig. 1C).

FIGURE 1.

FIGURE 1.

Open in a new tab

Galectin-1 interacts with cells expressing CD146. A, co-immunoprecipitation of CD146 with Galectin-1 in endothelial cells. Rabbit antiserum directed against Galectin-1 (IP Gal-1) was used to precipitate specific proteins in HUVEC. Western blot was revealed using either 7A4 anti-CD146 Mab or Galectin-1 antiserum. Pre-immune rabbit anti-serum was used as a control of the immunoprecipitation (IP control). B, colocalization of recombinant Galectin-1 and CD146 in CD146-transfected fibroblasts. Immunofluorescence staining of Galectin-1 (green, Gal-1, upper left picture), CD146 (red, CD146, lower left picture), differential interference contrast (DIC, upper right picture) and merged of Gal-1 and CD146 staining (merged, lower right picture). Staining was performed after incubation with recombinant Galectin-1 protein (5 μg/ml). Yellow staining on merged picture represents a colocalization of the two proteins. C, colocalization of endogenous Galectin-1 and CD146 in endothelial cells. Immunofluorescence staining of Galectin-1 (green, Gal-1, middle pictures), CD146 (red, CD146, left pictures), and merged of Gal-1 and CD146 staining (merged, right pictures). Staining was performed on sub-confluent endothelial progenitor cells. Arrow shows a co-localization of the two proteins.

The Interaction of Galectin-1 with CD146 Is Direct and Specific

To further determine whether the Galectin-1/CD146 interaction is direct, we performed biochemical assays using CD146-Fc (Fc-tagged CD146 extracellular domain) and soluble Galectin-1 (His-tagged Galectin-1). CD146-Fc was purified from supernatant of transiently transfected COS-7 cells. Coomassie Blue staining after SDS-PAGE separation showed that purity of the protein was more than 90% (Fig. 2A, left panel). Both CD146 and human-Fc moieties are detected by Western blot (Fig. 2A, right panel).

FIGURE 2.

FIGURE 2.

Open in a new tab

Galectin-1 directly interacts with CD146. A, quality and purity of CD146-Fc were assessed using Coomassie Blue staining and Western blotting. Left panel, in SDS-PAGE assay, 10, 5, and 1 μg of recombinant proteins were loaded in lanes 1, 2, and 3, respectively. Right panel, 10 ng of recombinant Fc were separated on SDS-PAGE and blotted with anti-CD146 (7A4 clone) antibody (lane 1) or anti-human Ig (lane 2). B, ELISA analysis of Galectin-1 interactions with immobilized CD146-Fc and irrelevant ICOS Ligand-Fc (ICOSL-Fc) proteins. Increasing concentrations of Galectin-1 were tested (from 1 to 50 μg/ml) and Galectin-2 was used as a control for binding specificity. C, SPR analysis of the interaction between CD146 and Galectin-1. Upper panel, Galectin-1 (1,7 μm) was injected for 2 min through CD146-Fc (black line) and ICOSL-Fc (dashed line) channels. Middle panel, serial concentrations of Galectin-1 (4 nm to 2 μm) were injected through both channels. Lower panel, value of the dissociation constant at the equilibrium is obtained by calculating the slope (−Kd) from a pseudo-Scatchard plotting of Req versus Req/C. The curves show the specific signal obtained after subtraction of the background.

Using ELISA assay, the interaction between CD146 and Galectin-1 was detected in a dose-dependent way, whereas no binding was observed with ICOS Ligand-Fc-coated plates, used as a negative control (Fig. 2B). ELISA assays demonstrated that Galectin-1 binds to CD146, whereas Galectin-2, which is structurally closely related to Galectin-1, does not (Fig. 2B). These data suggest a specific interaction between CD146 and Galectin-1, as Galectin proteins were expressed and purified according to the same protocol.

The surface plasmon resonance (SPR) study confirmed a direct interaction between CD146 and Galectin-1, whereas no binding was observed with ICOS Ligand-Fc (Fig. 2C, upper panel). Serial concentrations of Galectin-1 were used in SPR assay (Fig. 2C, middle panel) to determine the equilibrium dissociation constant. These data were plotted under a pseudo-Scatchard graph in which the slope of the line corresponds to the KD. The dissociation constant at the equilibrium (KD) was equal to 3.10−7 m (Fig. 2C, lower panel).

The Interaction of Galectin-1 with CD146 Is Dependent of Glycosylation Motifs

CD146 is a highly glycosylated protein as glycosylations account for about 35% of its apparent molecular weight. Moreover, Galectin-1 is able to establish bivalent or multivalent interactions with N- and O-glycans. Thus, we analyzed the glycosylation status of CD146-Fc protein. We investigated the potential shift of molecular weight of CD146-Fc exposed to either neuraminidase or glycosidases. A shift of CD146 molecular weight was observed using N-glycosidase whereas no change was observed using either neuraminidase or O-glycosidase (Fig. 3A). These data show that CD146-Fc protein is mainly N-glycosylated protein.

FIGURE 3.

FIGURE 3.

Open in a new tab

The interaction of Galectin-1 with CD146 is dependent of glycosylation motifs. A, Western blot analysis of CD146-Fc submitted to several glycosidase or neuraminidase treatments. A shift of CD146 molecular weight was observed using N-glycosidase. No change was detected using either neuraminidase or O-glycosidase treatments. B, ELISA analysis of the sugar-dependant binding of Galectin-1 to CD146. ELISA analysis of Galectin-1 interactions with immobilized recombinant CD146 proteins in the presence of either 0.2 m lactose or 0.2 m maltose. Galectin-2 was used as a control for binding specificity. C, SPR analysis of the sugar-dependent Galectin-1/CD146 interaction. 50 μg/ml of Galectin-1 was incubated with increasing amounts of lactose (upper panel) or maltose (lower panel) and then injected onto CD146 chip. Sensorgrams showing the binding of the Galectin-1 in the different situations are superimposed. Sensorgrams were aligned in the y and x axis at the beginning of injection. The data shown are representative of two separate experiments.

Galectin-1 can bind to its cognate ligands by regular interaction with β-galactoside sugars or by direct protein-protein interaction (40, 41). SPR and ELISA studies were performed in the presence of lactose, which is a competitor of Galectin-1 binding to β-galactosides. A dose-dependent inhibition of Galectin-1 binding to CD146-Fc was observed, whereas non-competing maltose had no effect (Fig. 3B, ELISA assay and Fig. 3C, SPR assay). These results indicate that glycosylation motifs are key players of the interaction.

CD146 Plays a Protective Role in Galectin-1-induced Endothelial Cell Apoptosis

To further investigate whether their interaction could affect endothelial cell apoptosis, we performed 7AAD/Annexin-V staining, used as markers for cell integrity and phosphatidylserine surface exposure. Apoptosis of HUVEC was increased after exposure to increasing concentrations of Galectin-1 (0, 2, 10, and 50 μg/ml), whereas Galectin-2 had a dose dependent effect even but in a lower extend (Fig. 4A). In addition, the Galectin-1 apoptotic effect on endothelial cells was confirmed using histones release quantification. HUVEC exposed to 5 and 10 μg/ml of Galectin-1 released cytoplasmic histones 2.78 ± 0.69 and 4.42 ± 0.19 times more than unstimulated HUVEC (control) (Fig. 4B).

FIGURE 4.

FIGURE 4.

Open in a new tab

CD146 protects Galectin-1-induced endothelial cell apoptosis. A, endothelial cell apoptosis was evaluated by 7AAD/Annexin-V staining at 24 h using increasing amounts of Galectin-1 (from 0 to 50 μg/ml) or Galectin-2, used as a negative control. B, endothelial cell apoptosis was evaluated by histone-associated-DNA-fragments released from HUVEC exposed during 6 h to 5 μg/ml and 10 μg/ml of Galectin-1 or 20 nm staurosporin, used as positive control, in comparison with basal conditions, without Galectin-1 (fold/cont). C, ribonucleic acid (RNA)-mediated silencing of CD146 in HUVEC. Western blot analysis (left panel) and flow cytometry analysis (right panel) showed down-modulation of CD146 expression. Right panel, CD146 expression on cells was analyzed by Mean Fluorescence Intensity (MFI). CD146 expression before transfection is represented on white peak (MFI = 103), CD146-siRNA-transfected cells on gray peak (MFI = 3) and control-siRNA-transfected cells on black peak (MFI = 88). Two independent transfections were shown in Western blot (lanes 1 and 2). D, CD146 plays a protective role in the Galectin-1-induced endothelial cell apoptosis. Endothelial cell apoptosis was evaluated by 7AAD/Annexin-V staining at 24 h using increasing amounts of Galectin-1 (from 0 to 50 μg/ml). Galectin-1 treatment was performed using either CD146 siRNA-silenced HUVEC or control siRNA-transfected HUVEC (left panel). The endothelial apoptosis, induced by Galectin-1 (20 μg/ml) for 24 h, is evaluated by the percentage of Annexin-V/7AAD-positive endothelial cells in comparison with basal conditions, without Galectin-1 (fold/cont) (right panel). E, endothelial cell apoptosis was evaluated by 7AAD/Annexin-V staining in HUVEC. Endothelial cells were treated with Galectin-1 (20 μg/ml) alone or after previous exposure to anti-CD146 antibody (S-Endo1 clone, 5 μg/ml). Exposure to anti-CD146 alone serves as a negative control. In A, B, D, and E panels, data are shown compared with control that corresponds to basal conditions without Galectin-1 stimulation.

To address the role of CD146 in Galectin-1-induced apoptosis, we did a specific siRNA silencing of CD146 using nucleofection of HUVEC. CD146-silenced HUVEC no longer expressed CD146 as demonstrated by the absence of CD146 staining, using both Western blot and flow cytometry, on transfected HUVEC (Fig. 4C). When CD146 was absent, HUVEC were more susceptible to apoptosis upon Galectin-1 treatment (Fig. 4D, left panel). This effect was dependent of the Galectin-1 concentration. Quantification of endothelial apoptotic cells after exposure to 20 μg/ml of Galectin-1 during 24 h showed a significant increase of apoptosis in CD146-silenced HUVEC (3.34 ± 0.17-fold/cont, n = 9) when compared with control siRNA-transfected HUVEC (1.95 ± 0.24-fold/cont, n = 5; p = 0.001) (Fig. 4D, right panel).

We further examined the contribution of CD146 in Galectin-1-induced endothelial apoptosis using blocking anti-CD146 antibody (S-Endo1 clone, 5 μg/ml) and its corresponding IgG isotypic control, at the same concentration. Endothelial cells were treated with Galectin-1 (20 μg/ml) alone or after previous exposure to anti-CD146 antibody. Incubation of HUVEC with the anti-CD146 antibody, before exposure to Galectin-1, significantly increased by 1.60 ± 0.34-fold (n = 5 each; p = 0.032) the percentage of Annexin-V/7AAD positive endothelial cells (Fig. 4E), whereas the addition of anti-CD146 alone did not affect endothelial apoptosis.

We further investigated the mechanisms by which CD146/Galectin-1 interaction modulates endothelial cell apoptosis. To determine whether this effect is caspase-dependent, the same experiment was performed using the caspase-family inhibitor Z-VAD-FMK. No significant effect on Galectin-1-induced apoptosis was detected in this setting (data not shown).

DISCUSSION

The present study identifies Galectin-1 as a novel ligand for CD146 and demonstrates that this interaction is involved in the control of endothelial cell apoptosis. We demonstrated that CD146 specifically interacts with Galectin-1 as no binding was detected with Galectin-2. Using real-time analysis by SPR, we determined a KD of 3.10−7 m for this interaction, consistent with reported affinity of Galectin-1 interaction to pre-BCR (41). It is known that Galectin-1 can bind either in a sugar-dependent or independent way to their ligands (22). We showed that CD146-Fc protein is sialylated and mainly N-glycosylated and that the lactose inhibits the interaction. Altogether, these results demonstrated that CD146 interacts with Galectin-1 in a sugar-dependent manner.

Many of the proposed regulatory effects of Galectin-1 appeared to involve reversible binding to receptors with affinities in the low μm range (42–45). In addition, Galectin-1 exhibits unique biochemical properties, which make its functional analysis even more complex. This protein contains unpaired cysteine residues in the CRD that, in the absence of carbohydrate binding activity, can form intramolecular disulfide bonds and thereby diminishes its known biological functions (22). Thus, glycan recognition partially protects Galectin-1 from oxidative inactivation and enhances Galectin-1 dimerization (46). Indeed, Galectin-1 exists as a mixture of monomers and dimers at physiological concentrations (45, 47). Therefore, the different functions of this lectin can be due to 1) the monomeric or dimeric form of this protein (45, 47–50), 2) the influence of oxidative versus reducing microenvironments (46), 3) the engagement of Galectin-1 with ligands (51), and 4) the in vivo levels of Galectin-1 in physiological and pathological concentrations.

In this study, we showed that high levels of exogenous Galectin-1 displays, in vitro, a pro-apoptotic effect on endothelial cells (micromolar range concentration), consistent with the pro-apoptotic effect of Galectin-1 described on other cell types. Exogenous Galectin-1 has been previously described to have a biphasic effect on the growth of distinct cell types including endothelial cells. Whereas low concentrations (nanomolar range) induced cell proliferation, high concentrations (micromolar range, equivalent to 20 μg/ml) of Galectin-1 seemed to have inhibitory effects (48, 52–57). Previous studies have shown that endothelial cells secrete Galectin-1 at the ng/ml level upon inflammatory conditions (56). Nevertheless, once secreted, Galectin-1 rapidly binds to the surface of the secreting or neighboring cells or to components of extracellular matrix. As Galectin-1 remains bound to cell or extracellular matrix glycoconjugates, determination of the local concentration of Galectin-1 is basically impossible. Thus, we could hypothesize that, during high inflammatory situation, endothelial cells can be locally exposed to high concentration of Galectin-1.

Beside its role in endothelial cell permeability and angiogenesis, CD146 overexpression has also been associated with survival signals such as Akt phosphorylation and down-modulation of Bad expression (37). Along the same line, Galectin-1 pro-apoptotic effect has already been described for human activated T lymphocytes (36) in which CD45 and CD43 bind to Galectin-1, inducing the activation of AP-1 transcription factor and the down-modulation of bcl-2 proteins (35). However, the mechanisms of Galectin-1 induced apoptosis are still debated since lower and higher amounts of the protein might act on different transmitting receptors, resulting in diverse apoptotic pathways. For instance, apoptosis induced by low levels of Galectin-1, but not high, was inhibited with the pan-caspase inhibitor, zVAD-FMK, which corroborates our results (58).

Interestingly, both Galectin-1 and CD146 endothelial cell expressions are increased in inflammatory conditions (12, 59) and we demonstrated that the absence of CD146 renders endothelial cells more susceptible to Galectin-1-induced apoptosis as both down-regulation of CD146 cell surface expression using siRNA and antibody-mediated blockade of CD146 increased Galectin-1-induced endothelial cell apoptosis.

Thus, it is tempting to speculate that the CD146 mucin could be a decoy receptor for Galectin-1, avoiding the Galectin-1 binding to pro-apoptotic receptors. By scavenging Galectin-1, CD146 could also protect Galectin-1 sensitivity to oxidation or enhances Galectin-1 dimer formation, which could display additional or different effects on endothelium. Indeed, dimeric Galectin-1 was shown to induce surface exposure of phosphatidylserine at the plasma membrane of leukemic and promyelocytic cells without inducing apoptosis (36, 60). On the other hand, it is conceivable that CD146 cross-linking by dimeric Galectin-1 participates to its role in VEGFR2 signaling involved in survival pathway (33). Altogether, our results identified Galectin-1 as a novel ligand for CD146 and demonstrated that its interaction with Galectin-1 protects endothelium from Galectin-1-induced apoptosis.

*

This work was supported by institutional resources provided by Aix-Marseille University, INSERM and by a grant from the Fondation de France.

5
The abbreviations used are:
MCAM
melanoma cell adhesion molecule
HUVEC
human umbilical vein endothelial cells
FAK
focal adhesion kinase
EDC/NHS
(N-ethyl-N′-3-dimethylaminopropyl) carbodiimidehydrochloride and N-hydroxysuccinimide
SPR
surface plasmon resonance.

REFERENCES

  • 1. Shih I. M. (1999) The role of CD146 (Mel-CAM) in biology and pathology. J. Pathol. 189, 4–11 [DOI] [PubMed] [Google Scholar]
  • 2. George F., Brisson C., Poncelet P., Laurent J. C., Massot O., Arnoux D., Ambrosi P., Klein-Soyer C., Cazenave J. P., Sampol J. (1992) Rapid isolation of human endothelial cells from whole blood using S-Endo1 monoclonal antibody coupled to immuno-magnetic beads: demonstration of endothelial injury after angioplasty. Thromb. Haemost 67, 147–153 [PubMed] [Google Scholar]
  • 3. Aldovini D., Demichelis F., Doglioni C., Di Vizio D., Galligioni E., Brugnara S., Zeni B., Griso C., Pegoraro C., Zannoni M., Gariboldi M., Balladore E., Mezzanzanica D., Canevari S., Barbareschi M. (2006) M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int. J. Cancer 119, 1920–1926 [DOI] [PubMed] [Google Scholar]
  • 4. Covas D. T., Panepucci R. A., Fontes A. M., Silva W. A., Jr., Orellana M. D., Freitas M. C., Neder L., Santos A. R., Peres L. C., Jamur M. C., Zago M. A. (2008) Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp. Hematol. 36, 642–654 [DOI] [PubMed] [Google Scholar]
  • 5. Johnson J. P., Bar-Eli M., Jansen B., Markhof E. (1997) Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. Int. J. Cancer 73, 769–774 [DOI] [PubMed] [Google Scholar]
  • 6. Kristiansen G., Yu Y., Schlüns K., Sers C., Dietel M., Petersen I. (2003) Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal. Cell. Pathol. 25, 77–81 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Pickl W. F., Majdic O., Fischer G. F., Petzelbauer P., Faé I., Waclavicek M., Stöckl J., Scheinecker C., Vidicki T., Aschauer H., Johnson J. P., Knapp W. (1997) MUC18/MCAM (CD146), an activation antigen of human T lymphocytes. J. Immunol. 158, 2107–2115 [PubMed] [Google Scholar]
  • 8. Wu Z., Li J., Yang X., Wang Y., Yu Y., Ye J., Xu C., Qin W., Zhang Z. (2012) MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumour. Biol. 33, 1619–1628 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Zabouo G., Imbert A. M., Jacquemier J., Finetti P., Moreau T., Esterni B., Birnbaum D., Bertucci F., Chabannon C. (2009) CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res. 11, R1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Anfosso F., Bardin N., Francès V., Vivier E., Camoin-Jau L., Sampol J., Dignat-George F. (1998) Activation of human endothelial cells via S-endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125(FAK). J. Biol. Chem. 273, 26852–26856 [DOI] [PubMed] [Google Scholar]
  • 11. Bardin N., Anfosso F., Massé J. M., Cramer E., Sabatier F., Le Bivic A., Sampol J., Dignat-George F. (2001) Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 98, 3677–3684 [DOI] [PubMed] [Google Scholar]
  • 12. Bardin N., Blot-Chabaud M., Despoix N., Kebir A., Harhouri K., Arsanto J. P., Espinosa L., Perrin P., Robert S., Vely F., Sabatier F., Le Bivic A., Kaplanski G., Sampol J., Dignat-George F. (2009) CD146 and its soluble form regulate monocyte transendothelial migration. Arterioscler. Thromb. Vasc. Biol. 29, 746–753 [DOI] [PubMed] [Google Scholar]
  • 13. Harhouri K., Kebir A., Guillet B., Foucault-Bertaud A., Voytenko S., Piercecchi-Marti M. D., Berenguer C., Lamy E., Vely F., Pisano P., Ouafik L., Sabatier F., Sampol J., Bardin N., Dignat-George F., Blot-Chabaud M. (2010) Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood 115, 3843–3851 [DOI] [PubMed] [Google Scholar]
  • 14. Kebir A., Harhouri K., Guillet B., Liu J. W., Foucault-Bertaud A., Lamy E., Kaspi E., Elganfoud N., Vely F., Sabatier F., Sampol J., Pisano P., Kruithof E. K., Bardin N., Dignat-George F., Blot-Chabaud M. (2010) CD146 short isoform increases the proangiogenic potential of endothelial progenitor cells in vitro and in vivo. Circ. Res. 107, 66–75 [DOI] [PubMed] [Google Scholar]
  • 15. Solovey A. N., Gui L., Chang L., Enenstein J., Browne P. V., Hebbel R. P. (2001) Identification and functional assessment of endothelial P1H12. J. Lab. Clin. Med. 138, 322–331 [DOI] [PubMed] [Google Scholar]
  • 16. Anfosso F., Bardin N., Vivier E., Sabatier F., Sampol J., Dignat-George F. (2001) Outside-in signaling pathway linked to CD146 engagement in human endothelial cells. J. Biol. Chem. 276, 1564–1569 [DOI] [PubMed] [Google Scholar]
  • 17. Guezguez B., Vigneron P., Lamerant N., Kieda C., Jaffredo T., Dunon D. (2007) Dual role of melanoma cell adhesion molecule (MCAM)/CD146 in lymphocyte endothelium interaction: MCAM/CD146 promotes rolling via microvilli induction in lymphocyte and is an endothelial adhesion receptor. J. Immunol. 179, 6673–6685 [DOI] [PubMed] [Google Scholar]
  • 18. Staquicini F. I., Tandle A., Libutti S. K., Sun J., Zigler M., Bar-Eli M., Aliperti F., Pérez E. C., Gershenwald J. E., Mariano M., Pasqualini R., Arap W., Lopes J. D. (2008) A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res. 68, 8419–8428 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Flanagan K., Fitzgerald K., Baker J., Regnstrom K., Gardai S., Bard F., Mocci S., Seto P., You M., Larochelle C., Prat A., Chow S., Li L., Vandevert C., Zago W., Lorenzana C., Nishioka C., Hoffman J., Botelho R., Willits C., Tanaka K., Johnston J., Yednock T. (2012) Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS. PLoS One 7, e40443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Almkvist J., Karlsson A. (2004) Galectins as inflammatory mediators. Glycoconj J. 19, 575–581 [DOI] [PubMed] [Google Scholar]
  • 21. Barondes S. H., Castronovo V., Cooper D. N., Cummings R. D., Drickamer K., Feizi T., Gitt M. A., Hirabayashi J., Hughes C., Kasai K. (1994) Galectins: a family of animal β-galactoside-binding lectins. Cell 76, 597–598 [DOI] [PubMed] [Google Scholar]
  • 22. Camby I., Le Mercier M., Lefranc F., Kiss R. (2006) Galectin-1: a small protein with major functions. Glycobiology 16, 137R-157R [DOI] [PubMed] [Google Scholar]
  • 23. Elola M. T., Wolfenstein-Todel C., Troncoso M. F., Vasta G. R., Rabinovich G. A. (2007) Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol. Life Sci. 64, 1679–1700 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Rabinovich G. A., Ilarregui J. M. (2009) Conveying glycan information into T-cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments. Immunol. Rev. 230, 144–159 [DOI] [PubMed] [Google Scholar]
  • 25. Thijssen V. L., Postel R., Brandwijk R. J., Dings R. P., Nesmelova I., Satijn S., Verhofstad N., Nakabeppu Y., Baum L. G., Bakkers J., Mayo K. H., Poirier F., Griffioen A. W. (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. U.S.A. 103, 15975–15980 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Chan B., Sinha S., Cho D., Ramchandran R., Sukhatme V. P. (2005) Critical roles of CD146 in zebrafish vascular development. Dev. Dyn 232, 232–244 [DOI] [PubMed] [Google Scholar]
  • 27. Yan X., Lin Y., Yang D., Shen Y., Yuan M., Zhang Z., Li P., Xia H., Li L., Luo D., Liu Q., Mann K., Bader B. L. (2003) A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 102, 184–191 [DOI] [PubMed] [Google Scholar]
  • 28. Braeuer R. R., Shoshan E., Kamiya T., Bar-Eli M. (2012) The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Melanoma Res. 25, 592–601 [DOI] [PubMed] [Google Scholar]
  • 29. Cedeno-Laurent F., Opperman M. J., Barthel S. R., Hays D., Schatton T., Zhan Q., He X., Matta K. L., Supko J. G., Frank M. H., Murphy G. F., Dimitroff C. J. (2012) Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J Invest Dermatol 132, 410–420 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Yang H., Wang S., Liu Z., Wu M. H., McAlpine B., Ansel J., Armstrong C., Wu G. (2001) Isolation and characterization of mouse MUC18 cDNA gene, and correlation of MUC18 expression in mouse melanoma cell lines with metastatic ability. Gene 265, 133–145 [DOI] [PubMed] [Google Scholar]
  • 31. Fischer I., Schulze S., Kuhn C., Friese K., Walzel H., Markert U. R., Jeschke U. (2009) Inhibiton of RET and JAK2 signals and upregulation of VEGFR3 phosphorylation in vitro by galectin-1 in trophoblast tumor cells BeWo. Placenta 30, 1078–1082 [DOI] [PubMed] [Google Scholar]
  • 32. Hsieh S. H., Ying N. W., Wu M. H., Chiang W. F., Hsu C. L., Wong T. Y., Jin Y. T., Hong T. M., Chen Y. L. (2008) Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 27, 3746–3753 [DOI] [PubMed] [Google Scholar]
  • 33. Jiang T., Zhuang J., Duan H., Luo Y., Zeng Q., Fan K., Yan H., Lu D., Ye Z., Hao J., Feng J., Yang D., Yan X. (2012) CD146 is a co-receptor for VEGFR-2 in tumor angiogenesis. Blood 120, 2230–2239 [DOI] [PubMed] [Google Scholar]
  • 34. Thijssen V. L., Hulsmans S., Griffioen A. W. (2008) The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am. J. Pathol. 172, 545–553 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Brandt B., Abou-Eladab E. F., Tiedge M., Walzel H. (2010) Role of the JNK/c-Jun/AP-1 signaling pathway in galectin-1-induced T-cell death. Cell Death Dis. 1, e23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Perillo N. L., Pace K. E., Seilhamer J. J., Baum L. G. (1995) Apoptosis of T cells mediated by galectin-1. Nature 378, 736–739 [DOI] [PubMed] [Google Scholar]
  • 37. Ouhtit A., Gaur R. L., Abd Elmageed Z. Y., Fernando A., Thouta R., Trappey A. K., Abdraboh M. E., El-Sayyad H. I., Rao P., Raj M. G. (2009) Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim. Biophys. Acta 1795, 130–136 [DOI] [PubMed] [Google Scholar]
  • 38. Jaffe E. A., Nachman R. L., Becker C. G., Minick C. R. (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52, 2745–2756 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Despoix N., Walzer T., Jouve N., Blot-Chabaud M., Bardin N., Paul P., Lyonnet L., Vivier E., Dignat-George F., Vély F. (2008) Mouse CD146/MCAM is a marker of natural killer cell maturation. Eur. J. Immunol. 38, 2855–2864 [DOI] [PubMed] [Google Scholar]
  • 40. Rossi B., Espeli M., Schiff C., Gauthier L. (2006) Clustering of pre-B cell integrins induces galectin-1-dependent pre-B cell receptor relocalization and activation. J. Immunol. 177, 796–803 [DOI] [PubMed] [Google Scholar]
  • 41. Gauthier L., Rossi B., Roux F., Termine E., Schiff C. (2002) Galectin-1 is a stromal cell ligand of the pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR triggering. Proc. Natl. Acad. Sci. U.S.A. 99, 13014–13019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Cederfur C., Salomonsson E., Nilsson J., Halim A., Oberg C. T., Larson G., Nilsson U. J., Leffler H. (2008) Different affinity of galectins for human serum glycoproteins: galectin-3 binds many protease inhibitors and acute phase proteins. Glycobiology 18, 384–394 [DOI] [PubMed] [Google Scholar]
  • 43. Hirabayashi J., Hashidate T., Arata Y., Nishi N., Nakamura T., Hirashima M., Urashima T., Oka T., Futai M., Muller W. E., Yagi F., Kasai K. (2002) Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim. Biophys. Acta 1572, 232–254 [DOI] [PubMed] [Google Scholar]
  • 44. Leppänen A., Stowell S., Blixt O., Cummings R. D. (2005) Dimeric galectin-1 binds with high affinity to α2,3-sialylated and non-sialylated terminal N-acetyllactosamine units on surface-bound extended glycans. J. Biol. Chem. 280, 5549–5562 [DOI] [PubMed] [Google Scholar]
  • 45. Salomonsson E., Larumbe A., Tejler J., Tullberg E., Rydberg H., Sundin A., Khabut A., Frejd T., Lobsanov Y. D., Rini J. M., Nilsson U. J., Leffler H. (2010) Monovalent interactions of galectin-1. Biochemistry 49, 9518–9532 [DOI] [PubMed] [Google Scholar]
  • 46. Stowell S. R., Cho M., Feasley C. L., Arthur C. M., Song X., Colucci J. K., Karmakar S., Mehta P., Dias-Baruffi M., McEver R. P., Cummings R. D. (2009) Ligand reduces galectin-1 sensitivity to oxidative inactivation by enhancing dimer formation. J. Biol. Chem. 284, 4989–4999 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Leffler H., Carlsson S., Hedlund M., Qian Y., Poirier F. (2004) Introduction to galectins. Glycoconj. J. 19, 433–440 [DOI] [PubMed] [Google Scholar]
  • 48. Adams L., Scott G. K., Weinberg C. S. (1996) Biphasic modulation of cell growth by recombinant human galectin-1. Biochim. Biophys. Acta 1312, 137–144 [DOI] [PubMed] [Google Scholar]
  • 49. Barrionuevo P., Beigier-Bompadre M., Ilarregui J. M., Toscano M. A., Bianco G. A., Isturiz M. A., Rabinovich G. A. (2007) A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J. Immunol. 178, 436–445 [DOI] [PubMed] [Google Scholar]
  • 50. Levroney E. L., Aguilar H. C., Fulcher J. A., Kohatsu L., Pace K. E., Pang M., Gurney K. B., Baum L. G., Lee B. (2005) Novel innate immune functions for galectin-1: galectin-1 inhibits cell fusion by Nipah virus envelope glycoproteins and augments dendritic cell secretion of proinflammatory cytokines. J. Immunol. 175, 413–420 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Stowell S. R., Arthur C. M., Mehta P., Slanina K. A., Blixt O., Leffler H., Smith D. F., Cummings R. D. (2008) Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens. J. Biol. Chem. 283, 10109–10123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Burns J. S., Kristiansen M., Kristensen L. P., Larsen K. H., Nielsen M. O., Christiansen H., Nehlin J., Andersen J. S., Kassem M. (2011) Decellularized matrix from tumorigenic human mesenchymal stem cells promotes neovascularization with galectin-1 dependent endothelial interaction. PLoS One 6, e21888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Dings R. P., Van Laar E. S., Loren M., Webber J., Zhang Y., Waters S. J., Macdonald J. R., Mayo K. H. (2010) Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjug. Chem. 21, 20–27 [DOI] [PubMed] [Google Scholar]
  • 54. Ito K., Scott S. A., Cutler S., Dong L. F., Neuzil J., Blanchard H., Ralph S. J. (2011) Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis 14, 293–307 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Sakaguchi M., Shingo T., Shimazaki T., Okano H. J., Shiwa M., Ishibashi S., Oguro H., Ninomiya M., Kadoya T., Horie H., Shibuya A., Mizusawa H., Poirier F., Nakauchi H., Sawamoto K., Okano H. (2006) A carbohydrate-binding protein, Galectin-1, promotes proliferation of adult neural stem cells. Proc. Natl. Acad. Sci. U.S.A. 103, 7112–7117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Thijssen V. L., Barkan B., Shoji H., Aries I. M., Mathieu V., Deltour L., Hackeng T. M., Kiss R., Kloog Y., Poirier F., Griffioen A. W. (2010) Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 70, 6216–6224 [DOI] [PubMed] [Google Scholar]
  • 57. Vas V., Fajka-Boja R., Ion G., Dudics V., Monostori E., Uher F. (2005) Biphasic effect of recombinant galectin-1 on the growth and death of early hematopoietic cells. Stem Cells 23, 279–287 [DOI] [PubMed] [Google Scholar]
  • 58. Blaskó A., Fajka-Boja R., Ion G., Monostori E. (2011) How does it act when soluble? Critical evaluation of mechanism of galectin-1 induced T-cell apoptosis. Acta Biol. Hung 62, 106–111 [DOI] [PubMed] [Google Scholar]
  • 59. Baum L. G., Seilhamer J. J., Pang M., Levine W. B., Beynon D., Berliner J. A. (1995) Synthesis of an endogeneous lectin, galectin-1, by human endothelial cells is up-regulated by endothelial cell activation. Glycoconj J. 12, 63–68 [DOI] [PubMed] [Google Scholar]
  • 60. Perillo N. L., Uittenbogaart C. H., Nguyen J. T., Baum L. G. (1997) Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J. Exp. Med. 185, 1851–1858 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES